NUVB
Nuvation Bio Inc.
There isn't enough reported data to score NUVB yet.
NUVB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
NUVB's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
NUVB PE Valuation
NUVB has no meaningful PE right now: it lost money over the past year.
NUVB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NUVB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NUVB Earnings Per Share
NUVB lost $0.49 per share over the past year, a bigger loss than the year before.
NUVB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45M | +243% |
| Q2 2026 | $31.7M | +556% |
| Q1 2026 | $83.2M | +2599% |
| Q4 2025 | $41.9M | +633% |
| Q3 2025 | $13.1M | +1705% |
| Q2 2025 | $4.8M | +237% |
NUVB's revenue has grown year over year every quarter since late 2024: $45M last quarter, up 243% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | +336 points |
| Q2 2026 | -161% | +1155 points |
| Q1 2026 | 4.7% | +1918 points |
| Q4 2025 | -81% | +863 points |
| Q3 2025 | -430% | +6186 points |
| Q2 2025 | -1316% | +31464 points |
| Q1 2025 | -1913% | N/A |
| Q4 2024 | -945% | N/A |
NUVB's operating margin was −94% last quarter, up 336 points from the same quarter a year ago.
NUVB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$43M | +$5.2M |
| Q1 2026 | $5.1M | +$47.7M |
| Q4 2025 | -$29.7M | +$16.6M |
| Q2 2025 | -$48.2M | -$10.9M |
| Q1 2025 | -$42.6M | -$26.9M |
| Q4 2024 | -$46.3M | -$31.3M |
| Q3 2024 | -$31.1M | -$14.9M |
| Q2 2024 | -$37.3M | -$19.8M |
NUVB has burned cash in almost every quarter: −$116M over the past year, against −$157M the year before.
NUVB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.3% | -19.7M shares |
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NUVB Net Leverage
NUVB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NUVB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 6.8 | Oversold |
NUVB's weekly RSI is 35 (neutral) and its Stochastic is 7 (oversold).
NUVB PE vs Healthcare Sector
NUVB has no meaningful PE right now: it lost money over the past year.
NUVB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 14% below |
| 20 week MA | $5.65 | 28% below |
| 50 week MA | $5.71 | 29% below |
| 100 week MA | $4.29 | 5.4% below |
| 200 week MA | $3.22 | 26% above |
NUVB has fallen below most of its moving averages, though it's still 26% above its 200-week average.
NUVB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.95 | $10.6 | +6.4% |
| 2021 | $10.6 | $8.23 | -22% |
| 2022 | $8.23 | $1.77 | -78% |
| 2023 | $1.77 | $1.51 | -15% |
| 2024 | $1.51 | $2.76 | +83% |
| 2025 | $2.76 | $9.40 | +241% |
| 2026 YTD | $9.40 | $4.06 | -57% |
NUVB's yearly returns have swung widely, from +241% in 2025 to −78% in 2022. It's down 57% so far in 2026.